ArticleFrontiers in endocrinology2026
Decitabine modulates dopamine agonist sensitivity in gh3 rat pituitary tumor cells via Trim7.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pituitary prolactinoma is the most prevalent subtype of functional pituitary adenoma, for which dopamine agonists (DAs) have been established as the universal first-line therapeutic regimen in clinical practice. Approximately 10-25% of patients exhibit poor therapeutic responsiveness to DAs, presenting with persistent hyperprolactinemia and uncontrolled tumor growth, while the molecular mechanisms underlying this drug resistance phenotype remain incompletely characterized. Methods: In the present study, GH3 rat pituitary tumor cells were employed as the in vitro experimental model to investigate whether the DNA methyltransferase inhibitor decitabine could modulate cellular sensitivity to dopamine agonists, and to further elucidate the associated potential molecular basis. Transcriptome sequencing coupled with systematic bioinformatics analysis was conducted on GH3 cells after decitabine intervention to screen candidate differentially expressed genes, from which Trim7 was selected as the key target for subsequent functional validation. Results: Functional assays demonstrated that Trim7 overexpression significantly enhanced cabergoline-induced apoptosis in GH3 cells. A concomitant reduction in cell proliferation was also observed in the Trim7 overexpression group compared with the empty vector control, although this difference did not reach statistical significance. Discussion: Collectively, these data establish a significant correlative relationship between Trim7 upregulation and improved dopamine agonist sensitivity in GH3 cells. Complementary loss-of-function experiments are still required to define the definitive causal role of Trim7 in this regulatory axis. The present findings provide preliminary evidence for the involvement of epigenetic regulation in dopamine agonist resistance, and suggest that Trim7 may serve as a promising potential therapeutic target for future intervention strategies in drug-resistant prolactinomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.